Glofitamab Monotherapy Demonstrates High Complete Response Rates and Manageable Safety in Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies
- Resource Type
- Abstract
- Source
- In
Blood 15 November 2022 140 Supplement 1:12050-12051 - Subject
- Language
- ISSN
- 0006-4971